TY - JOUR
T1 - Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
T2 - Flatiron Database Analysis
AU - Patt, Debra
AU - Liu, Xianchen
AU - Li, Benjamin
AU - McRoy, Lynn
AU - Layman, Rachel M.
AU - Brufsky, Adam
N1 - Funding Information:
Editorial support was provided by John Teiber, PhD, of ICON plc (North Wales, PA, USA). This study was funded by Pfizer Inc, which contributed to the study design, the collection, analysis and interpretation of data, the writing of the manuscript, and in the decision to submit the article for publication.
Publisher Copyright:
© 2022
PY - 2022/8
Y1 - 2022/8
N2 - Introduction: To describe real-world treatment patterns and effectiveness of first-line palbociclib plus an aromatase inhibitor (PAL+AI) and examine the association between PAL initial dose and effectiveness among patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic/advanced breast cancer (HR+/HER2– MBC) in routine clinical practice. Patients and Methods: This retrospective analysis used Flatiron Health's database of electronic health records from >280 cancer clinics representing >2.4 million actively treated cancer patients in the United States. Women with HR+/HER2− MBC who received first-line PAL+AI were included. Real-world progression-free survival (rwPFS) was defined as the time from starting PAL+AI to death or disease progression. Real-world best tumor response (rwBTR) was assessed based on the treating clinician's assessment of radiologic evidence for change in disease burden. Results: Of 813 eligible patients, median age was 65.0 years, and median follow-up was 21.0 months. PAL was initiated at 125 mg/d and 75/100 mg/d in 86.5% and 13.5% of patients, respectively. Median duration of PAL+AI was 16.3 months. 43.0% of patients discontinued PAL+ AI; 11.0% discontinued because of toxicity. Median time to subsequent therapy and chemotherapy was 24.6 and 36.6 months, respectively. Median rwPFS was 20.0 months, and best rwBTR rate was 51.9%. Patients starting PAL at 125 versus 75/100 mg/d had longer median rwPFS (27.8 vs. 18.6 months) and higher rwBTR rate (54.0% vs. 40.4%). Conclusion: These data demonstrate the benefit of PAL+AI in routine clinical practice and may support the initiation of palbociclib at the recommended dose of 125 mg/d for HR+/HER2− MBC.
AB - Introduction: To describe real-world treatment patterns and effectiveness of first-line palbociclib plus an aromatase inhibitor (PAL+AI) and examine the association between PAL initial dose and effectiveness among patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic/advanced breast cancer (HR+/HER2– MBC) in routine clinical practice. Patients and Methods: This retrospective analysis used Flatiron Health's database of electronic health records from >280 cancer clinics representing >2.4 million actively treated cancer patients in the United States. Women with HR+/HER2− MBC who received first-line PAL+AI were included. Real-world progression-free survival (rwPFS) was defined as the time from starting PAL+AI to death or disease progression. Real-world best tumor response (rwBTR) was assessed based on the treating clinician's assessment of radiologic evidence for change in disease burden. Results: Of 813 eligible patients, median age was 65.0 years, and median follow-up was 21.0 months. PAL was initiated at 125 mg/d and 75/100 mg/d in 86.5% and 13.5% of patients, respectively. Median duration of PAL+AI was 16.3 months. 43.0% of patients discontinued PAL+ AI; 11.0% discontinued because of toxicity. Median time to subsequent therapy and chemotherapy was 24.6 and 36.6 months, respectively. Median rwPFS was 20.0 months, and best rwBTR rate was 51.9%. Patients starting PAL at 125 versus 75/100 mg/d had longer median rwPFS (27.8 vs. 18.6 months) and higher rwBTR rate (54.0% vs. 40.4%). Conclusion: These data demonstrate the benefit of PAL+AI in routine clinical practice and may support the initiation of palbociclib at the recommended dose of 125 mg/d for HR+/HER2− MBC.
KW - Advanced breast cancer
KW - CDK4/6
KW - Metastatic breast cancer
KW - Palbociclib
KW - Real-world data
UR - http://www.scopus.com/inward/record.url?scp=85130965801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130965801&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2022.05.002
DO - 10.1016/j.clbc.2022.05.002
M3 - Article
C2 - 35643624
AN - SCOPUS:85130965801
SN - 1526-8209
VL - 22
SP - 601
EP - 610
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 6
ER -